Format

Send to

Choose Destination
See comment in PubMed Commons below
Curr Treat Options Oncol. 2013 Sep;14(3):365-73. doi: 10.1007/s11864-013-0240-x.

Controversy and consensus on the management of patients with pseudomyxoma peritonei.

Author information

1
Massachusetts General Hospital Cancer Center, Yawkey 7E 55 Fruit Street, Boston, MA, 02114, USA.

Abstract

OPINION STATEMENT:

Pseudomyxoma peritonei and peritoneal carcinomatosis derived from appendiceal epithelial tumors are controversial entities from classification to treatment. For the former entity, multiple classification systems have been attempted to distinguish indolent from more aggressive subtypes. The treatment of the low grade variants is managed with serial cytoreduction surgery, with data indicating possible, but unproven, benefit from heated intraperitoneal chemotherapy (HIPEC). There is no consensus on the role of cytoreduction and HIPEC for the management of the more aggressive histologic variants and peritoneal carcinomatosis. Currently, we believe systemic chemotherapy is the standard of care for patients with the high grade variants and peritoneal carcinomatosis.

PMID:
23934509
DOI:
10.1007/s11864-013-0240-x
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer
    Loading ...
    Support Center